GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: DS-7300 | I-DXd
Compound class:
Antibody
Comment: Ifinatamab deruxtecan (DS-7300) is a B7-H3 (CD276)-targeting antibody-drug conjugate (ADC) [1]. B7-H3 is an immuno-oncology molecular target in solid tumours. The deruxtecan conjugate is a camptothecin derivative that is used as a cytotoxic DNA topoisomerase 1 payload.
|
| No information available. |
Summary of Clinical Use  |
| Ifinatamab deruxtecan (DS-7300; I-DXd) is a clinical candidate. It is under investigation as an anti-tumour monotherapy and in combination with other anti-cancer agents. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | Phase 2 Interventional | Dana-Farber Cancer Institute | ||
| NCT06564844 | A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | Phase 3 Interventional | AstraZeneca | ||
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Phase 1/Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
